RA Capital Management Bets Another $20 Million On Kala Pharmaceuticals Inc.

Page 3 of 5 – SEC Filing

CUSIP No. 483119103

1	Names of Reporting Persons.   Peter Kolchinsky
2	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a)      ¨
	(b)      ¨
3	SEC Use Only
4	Source of Funds (See Instructions): AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e): ¨
6	Citizenship or Place of Organization.      United States

Number of Shares Beneficially Owned by Each Reporting Person With	7      Sole Voting Power      0 shares
	8      Shared Voting Power      4,537,478 shares
	9      Sole Dispositive Power      0 shares
	10    Shared Dispositive Power      4,537,478 shares

11	Aggregate Amount Beneficially Owned by Each Reporting Person 4,537,478 shares
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)     ¨
13	Percent of Class Represented by Amount in Row (11) 14.1%2
14	Type of Reporting Person (See Instructions) HC, IN

² The reporting person is
the beneficial owner of 4,537,478 shares of the Issuer’s Common Stock which constitute approximately 14.1% of the class
outstanding. The percentage calculation assumes that there are currently 32,106,674 outstanding shares of Common Stock of the
Issuer, based on the Issuer’s Prospectus as filed with the Securities and Exchange Commission (“SEC”) on October
3, 2018.

Follow Kala Bio Inc. (NASDAQ:KALA)

Follow Kala Bio Inc. (NASDAQ:KALA)

---

or

Subscribe with Google

We may use your email to send marketing emails about our services. Click here to read our privacy policy.